Mankind Pharma's Strategic Acquisition of Bharat Serums and Vaccines

Mankind Pharma is set to fully acquire Bharat Serums and Vaccines (BSV) for Rs 13,630 crore. The acquisition aims to drive future growth and add significant value to Mankind’s portfolio, especially in women's health and fertility. The deal will be financed through internal accruals, equity, and debt.

Mankind Pharma has announced the acquisition of Bharat Serums and Vaccines (BSV) for an enterprise value of Rs 13,630 crore, according to Vice Chairman and Managing Director Rajeev Juneja. The deal seeks to bolster the company's growth, particularly in specialized sectors like women's health and fertility. Juneja emphasized that the acquisition is strategically aligned with Mankind's aim to enter high-barrier markets.

Funding for the acquisition will come from a mix of internal accruals, equity, and debt, with Rs 4,000 crore expected from internal sources. The acquisition will enable Mankind Pharma to strengthen its portfolio with BSV's established products in women's health, fertility, and critical care.

BSV's robust branded product line and market leadership in specialized health sectors will complement Mankind's existing therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and antidiabetic segments. The acquisition is poised to solidify Mankind's market position and expand its reach in rapidly growing, under-penetrated markets.

(With inputs from agencies.)